New study monitors OBIZUR's safety in rare bleeding disorder
NCT ID NCT06550882
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is checking how safe OBIZUR is for adults with acquired hemophilia A, a rare condition that causes sudden and severe bleeding. Researchers will look at medical records and track side effects in about 9 people. The goal is to see how well the drug controls bleeding in everyday medical practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACQUIRED HEMOPHILIA A are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ewha Womans University Medical Center
RECRUITINGSeoul, 07804, South Korea
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Kyung Hee University Hospital at Gangdong
RECRUITINGSeoul, 05278, South Korea
Contact Email: •••••@•••••
Contact
-
The Catholic University of Korea, Seoul St. Mary's Hospital
RECRUITINGSeoul, 06591, South Korea
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ulsan University Hospital
RECRUITINGUlsan, 44033, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.